Delivery Order SPE2DB20D3505-SPE2DB25FYCHF
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,186.32 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500 count) on September 2, 2025, with completion scheduled for September 3, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's broader indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical supply will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 500 units. This is a firm fixed-price delivery order with a ceiling value of $9,303.33 and an ultimate completion date of August 20, 2025. The contract is non-competitive and represents a direct purchase under AmerisourceBergen's existing indefinite delivery contract framework. The place of performance is listed as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 count) valued at $6,599.70. This is a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $13,399.76 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 15, 2025. Ondansetron is an antiemetic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ondansetron HCL 4 mg tablets (30-count packaging) with a contract value of $3,436.96. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract has an ultimate completion date...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Ondansetron HCL 4 mg tablets (500-count packages) valued at $13,519.08. This competitively awarded, firm fixed-price contract is non-set-aside and represents a child order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The place of performance is located at the vendor's corporate office in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 tablets) with a ceiling value of $5,367.10. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $35,990.01. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30, with a ceiling value of $23,438.54. This is a firm fixed price delivery order with no set-aside designation, completed through open competition. The order is scheduled for ultimate completion by September 2, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30 units. This contract, valued at $1,197.33, represents a firm fixed price delivery order with an ultimate completion date of August 28, 2025. The order will be fulfilled from AmerisourceBergen's facilities in Conshohocken, Pennsylvania. No set-aside designation was applied to this award, indicating it was competitively procured...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FYCHFDelivery Order
The Defense Logistics Agency (DLA) awarded a $11,073.06 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. Ondansetron, an antiemetic medication commonly used to prevent nausea and vomiting, represents the type of critical pharmaceutical commodity routinely procured through this strategic contract arrangement to support federal medical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.1k | 9/9/25 |